このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Lithium Countertransport and Blood Pressure In CARDIA and TOMHS

To conduct ancillary studies of sodium-stimulated lithium counter-transport in the Chicago components of the Coronary Heart Disease Risk Development in Young Adults (CARDIA) cohort and in the Treatment of Mild Hypertension Study (TOMHS) cohort.

調査の概要

詳細な説明

BACKGROUND:

CARDIA was a longitudinal study of the influence of lifestyle on coronary heart disease risk factors during the young adult and post-young-adult years, the time period during which risk for cardiovascular disease was thought to undergo crucial evolution. Four centers participated in this study. The Chicago CARDIA population consisted of 1,100 Black and white men and women age 18 to 30 at baseline, of diverse socioeconomic backgrounds.

TOMHS was a two phase double-blind randomized controlled clinical trial to determine whether pharmacologic therapy in conjunction with nutritional-hygienic intervention for persons with mild hypertension results in greater reduction of cardiovascular morbidity than nutritional-hygienic treatment alone. Four clinical centers were involved in Phase I. Participants were randomized into one of six treatment groups. Each group received nutritional-hygienic treatment plus one of the following: placebo, diuretic, alpha blocker, beta blocker, angiotensin-converting enzyme inhibitor, calcium channel blocker. Randomization was stratified to assure balance within each treatment group with regard to participants' drug treatment status prior to randomization. The primary endpoint was cardiovascular morbidity.

Abnormalities in cellular sodium metabolism have long been thought to play a role in the pathogenesis of hypertension. Techniques for measuring membrane electrolyte transport rates have been refined, providing an opportunity to characterize sodium metabolism in cells from hypertensives. The early clinical studies examined erythrocytes and leukocytes because of their easy accessibility and the possibility that they would reflect vascular tissue metabolism, and documented differences in sodium fluxes between hypertensives and normotensives. Subsequent studies have supported the early findings that abnormalities in membrane cation transport were associated with essential hypertension.

The findings up to 1988 indicated that one or more transport systems might be altered in essential hypertension but each system was not affected similarly, nor did all hypertensives show the same changes in each of the transport systems studied. The most consistent findings have been observed for sodium-stimulated lithium countertransport (LCT). Clinical and population-based studies have revealed that mean LCT is significantly elevated among hypertensives. In contrast, increased, decreased, and normal mean values have been reported for sodium cotransport, and increased or normal mean values for adenosine triphosphate (ATP)-dependent sodium-potassium pump activity.

The relationship between LCT and blood pressure has been examined in several studies. The largest of these was an epidemiological survey involving 3,800 men and women age 5 to over 75 in Gubbio, Italy. LCT was significantly and positively associated with both systolic and diastolic blood pressure in this population after controlling for age, sex, and weight, but, after controlling also for other factors known to be related to blood pressure such as serum uric acid and glucose, the relationship was inconsistently significant in this cross-sectional study. In other cross-sectional research, LCT was found to account for three percent of the variation in blood pressure in a study of healthy blood donors after adjustment for weight and age. Other cross-sectional population-based studies involving smaller numbers have shown a significant relationship between LCT and diastolic blood pressure in adolescents and in white adults, but not among Black adults; also between LCT and systolic blood pressure, but not diastolic blood pressure, in Black children and white adolescents.

Much of the data available in 1988 had been derived from small numbers in cross-sectional studies, chiefly clinical, only a few population-based. Large samples were needed to provide adequate power to detect relationships among LCT and demographic, dietary, and other factors. Prospective data were needed to assess whether LCT was an independent risk factor for future development of high blood pressure in people normotensive at baseline, whether LCT could be modified, and whether this change was associated with changes in blood pressure.

DESIGN NARRATIVE:

In the cross-sectional CARDIA investigation, studies were conducted on the relationships among lithium countertransport, blood pressure, and factors related to blood pressure such as age, sex, race, weight, body mass index, pulse, dietary factors, alcohol intake, serum glucose, triglycerides, cholesterol, high density lipoprotein cholesterol, uric acid, and ionized and total calcium. Prospective data were also collected from TOMHS to examine whether lithium countertransport was modified in mild hypertension by diet or by a combination of diet and antihypertensive drugs. Lithium countertransport was assayed in erythrocytes at the second examination in CARDIA and at baseline, 12 months, and 24 months in TOMHS.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

研究の種類

観察的

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

100年歳未満 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

説明

No eligibility criteria

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

1988年3月1日

研究の完了 (実際)

1990年2月1日

試験登録日

最初に提出

2000年5月25日

QC基準を満たした最初の提出物

2000年5月25日

最初の投稿 (見積もり)

2000年5月26日

学習記録の更新

投稿された最後の更新 (見積もり)

2016年3月16日

QC基準を満たした最後の更新が送信されました

2016年3月15日

最終確認日

2000年6月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • 1092
  • R01HL038256 (米国 NIH グラント/契約)

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

心臓疾患の臨床試験

3
購読する